The Release of Cytochrome c from Mitochondria during Apoptosis of NGF-Deprived Sympathetic Neurons Is a Reversible Event
During apoptosis induced by various stimuli, cytochrome c is released from mitochondria into the cytosol where it participates in caspase activation. This process has been proposed to be an irreversible consequence of mitochondrial permeability transition pore opening, which leads to mitochondrial s...
Saved in:
Published in | The Journal of cell biology Vol. 144; no. 5; pp. 883 - 889 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Rockefeller University Press
08.03.1999
The Rockefeller University Press |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | During apoptosis induced by various stimuli, cytochrome c is released from mitochondria into the cytosol where it participates in caspase activation. This process has been proposed to be an irreversible consequence of mitochondrial permeability transition pore opening, which leads to mitochondrial swelling and rupture of the outer mitochondrial membrane. Here we present data demonstrating that NGF-deprived sympathetic neurons protected from apoptosis by caspase inhibitors possess mitochondria which, though depleted of cytochrome c and reduced in size, remained structurally intact as viewed by electron microscopy. After reexposure of neurons to NGF, mitochondria recovered their normal size and their cytochrome c content, by a process requiring de novo protein synthesis. Altogether, these data suggest that depletion of cytochrome c from mitochondria is a controlled process compatible with function recovery. The ability of sympathetic neurons to recover fully from trophic factor deprivation provided irreversible caspase inhibitors have been present during the insult period, has therapeutical implications for a number of acute neuropathologies. |
---|---|
Bibliography: | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 Address correspondence to J.-C. Martinou, Serono Pharmaceutical Research Institute, Ares Serono International S.A., 14 chemin des Aulx, CH-1228 Plan-les-Ouates, Geneva, Switzerland. Tel.: (41) 22 706 9822. Fax: (41) 22 794 6965. E-mail: jean-claude.martinou.ch_gva03@serono.com |
ISSN: | 0021-9525 1540-8140 |
DOI: | 10.1083/jcb.144.5.883 |